Mentice Aims to Reduce TACE Procedure Times, Minimize Radiation with New TACE Simulation Training Solution
Mentice, the world’s leading endovascular simulation solution provider, has announced the release of a new simulation training software for transarterial chemoembolization (TACE). The new software will be showcased at the 2017 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress to be held September 16-20 in Copenhagen, Denmark.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170906005763/en/
Mentice transarterial chemoembolization training software – fluoro (Photo: Business Wire)
TACE is an effective, widely performed therapy performed by interventional radiologists (IRs). It is a minimally invasive procedure for liver cancer that delivers chemotherapy drugs and embolization agents with great accuracy, minimizing side effects for patients. It is however a challenging procedure that involves various sub-techniques, complex anatomies and variant vasculatures requiring the extensive use of radiation. Success of the procedure and impact on cost is tied to the ability to complete it safely and accurately within the permitted radiation doses.
“Conventional apprentice-based training in the clinical practice is costly, resource-intensive and can have an impact on patient safety,” comments Mentice CEO Göran Malmberg. “Our TACE software provides a safe, effective, repeatable and highly realistic solution—allowing IRs to have hands-on training outside of the cath lab.”
The Mentice TACE training solution is based on real-life cases, providing the realism essential for successful training and features an integrated radiation safety module, that provides dose monitoring for patient and staff at all times. The software also features output of metrics, enabling objective assessment of trainees’ progress. “Realistic high-fidelity simulation solutions are very effective for procedures such as TACE,” adds Malmberg. “Trainees can acquire the multi-level skills required to perform the procedure in a dose-dependent, time-effective way, reducing overall costs, while maintaining patient safety.”
Attendees at CIRSE can test the new Mentice TACE training software at the company’s booth (booth RPP1 at the Radiation Protection Pavilion). The software will also be available for testing and demonstrations at ‘The Basics of Chemoembolization for the Liver’ session being held as part of the ‘Principles to Practice: Education and Simulation Skills Training’ program.
To learn more about the new Mentice TACE training software please visit www.mentice.com/tace
To learn more about CIRSE 2017, please visit www.cirse.org
Mentice is the world leader in virtual reality-based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and preprocedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated, and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. Learn more about the features and benefits of Mentice solutions at: www.mentice.com.
Marketing Communications Manager
+46 (0) 31 339 94 94
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease 23.5.2018 07:00 | Pressemelding
For media excluding US/Canada and UK This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180523005102/en/ Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in patients living with COPD. VESUTO® and OTIVATO® data were presented during the American Thoracic Society meeting (ATS) and PHYSACTO® data was recently published in the American Journal of Respiratory and Critical Care Medicine.1,2,3 Activity-related breathlessness is a characteristic feature of COPD.5 It limits patients’ exercise tolerance and has an impact on their daily activities, which can lead to a downward spiral of exercise avoidance and physical decline.5,6 Decreased activity results in patients experiencing further breathlessness during even lower levels of physical activity, leading to further worsening of their condition, and increasing the risk of d
eLichens Raises EUR 7 Million to Boost its Growth in France and Internationally23.5.2018 06:00 | Pressemelding
Designer of patented gas sensors and the first comprehensive air quality analysis and prediction platform, eLichens today announced a new EUR 7 million capital increase with its historical investors and two new entrants. This operation, which follows the success of the first raising of capital of over 4 million euros in July 2016, aims to market large volumes of its micro gas sensors to serve the needs of its industrial customers as well as the large-scale deployment of its platform that performs intelligent indoor and outdoor air quality analysis for the smart city, smart home and smart building markets. The eLichens team relies on patented technologies developed jointly with renowned laboratories such as CEA-Leti and MIT. In addition to the renewed and strengthened support from current shareholders, including DEMETER, SOFIMAC Innovation, Business Angels networks (members of France Angels) and Aereco, eLichens is delighted to welcome the Fonds Ville de Demain managed by Bpifrance as p
Greenbird Named a Gartner Cool Vendor in Application Architecture, Infrastructure and Integration23.5.2018 05:05 | Pressemelding
Greenbird, the company delivering Metercloud to accelerate the energy revolution, today announced that it has been named a Gartner “Cool Vendor” in Application Architecture, Infrastructure and Integration. Greenbird empowers utilities by delivering Metercloud to manage the data flow faster and smoother than traditional system integration models. With prebuilt Metercloud integration applications and connectors, software solutions can be connected and updated in a few days instead of months of custom coding. Every year Gartner identifies Cool Vendors with innovative offerings for application leaders responsible for architecture, infrastructure and integration. Thorsten Heller, CEO and Co-Founder at Greenbird, said that “In the Cool Vendor report, Gartner recommends ‘application leaders responsible for modernizing application architecture, infrastructure and integration should exploit service mesh capabilities in portable, resilient and incrementally extensible microservices implementatio
Hilton Commits to Cutting Environmental Footprint in Half and Doubling Social Impact Investment23.5.2018 04:01 | Pressemelding
Hilton today announced it will cut its environmental footprint in half and double its social impact investment by 2030. With this commitment, Hilton will become the first major hotel company to institute science-based targets to reduce carbon emissions and send zero soap to landfill. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006472/en/ Hilton Commits to Cutting Environmental Footprint in Half and Doubling Social Impact Investment (Photo: Business Wire) The company will also double the amount it spends with local and minority-owned suppliers, and double its investment in programs to help women and youth around the world. These goals are part of Hilton’s Travel with Purpose corporate responsibility strategy to further the United Nation’s 2030 Sustainable Development Agenda. New consumer research reaffirms Hilton’s corporate responsibility strategy. According to a survey of 72,000 Hilton guests, social, environmental
General Cable Responds to Speculation Regarding Alleged Investigation23.5.2018 03:05 | Pressemelding
General Cable Corporation (NYSE: BGC) (“General Cable” or “the Company”) today issued the following statement in response to a recent press report about an alleged new investigation by the United States Department of Justice (DOJ): We are aware of a recent press report regarding an alleged new DOJ investigation under the United States Foreign Corrupt Practices Act (FCPA) involving General Cable. To the best of our knowledge, we have been and remain in compliance with the terms of our December 2016 Non-Prosecution Agreement (NPA) entered into with the DOJ. We periodically communicate with the DOJ as required by the NPA, and we are not aware of any new DOJ enforcement action or investigation against the Company at this time. Cautionary Statement Regarding Forward-Looking Statements Certain statements in this communication, including, without limitation, statements regarding the Company’s compliance with the NPA and any enforcement action or investigation against the Company, and manageme
Zephyr Endobronchial Valves Improve Breathing, Quality of Life and Activity for Severe Emphysema Patients in US Pivotal Trial22.5.2018 17:19 | Pressemelding
Pulmonx® Corp. today announced positive one-year results from the U.S. LIBERATE pivotal trial of the Zephyr® Endobronchial Valve, a minimally-invasive treatment for severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522006139/en/ Zephyr Endobronchial Valves (Photo: Business Wire) “The LIBERATE Study definitively proves that Zephyr Valves offer clinically meaningful improvements in three important areas for patients – the ability to breathe better, be more active, and enjoy an improved quality of life,” said the study’s lead investigator, Gerard Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University. He continued, “All primary and secondary endpoints were met, with Zephyr Valve treatment showing significant improvement for patients across multiple measures of breathing a